Presbia PLC (NASDAQ:LENS) was upgraded by ValuEngine from a “strong sell” rating to a “sell” rating in a research note issued to investors on Friday.

Other equities research analysts have also issued research reports about the stock. HC Wainwright reissued a “buy” rating and issued a $12.00 price objective on shares of Presbia PLC in a research report on Tuesday, May 23rd. Zacks Investment Research upgraded shares of Presbia PLC from a “sell” rating to a “hold” rating in a research note on Tuesday, July 25th. Finally, Rodman & Renshaw reduced their price objective on shares of Presbia PLC from $14.00 to $12.00 and set a “buy” rating on the stock in a research note on Monday, May 22nd. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the stock. Presbia PLC currently has an average rating of “Hold” and a consensus price target of $12.00.

Presbia PLC (NASDAQ:LENS) traded down 4.00% during mid-day trading on Friday, reaching $2.88. 9,718 shares of the company traded hands. The stock has a 50-day moving average of $2.48 and a 200 day moving average of $2.77. The stock’s market capitalization is $48.83 million. Presbia PLC has a 52-week low of $1.86 and a 52-week high of $4.97.

COPYRIGHT VIOLATION NOTICE: This report was posted by Watch List News and is the sole property of of Watch List News. If you are accessing this report on another website, it was illegally stolen and republished in violation of international copyright laws. The correct version of this report can be read at https://www.watchlistnews.com/presbia-plc-lens-upgraded-to-sell-at-valuengine/1537006.html.

An institutional investor recently raised its position in Presbia PLC stock. FMR LLC boosted its stake in Presbia PLC (NASDAQ:LENS) by 0.5% during the second quarter, according to its most recent disclosure with the SEC. The firm owned 2,568,278 shares of the medical instruments supplier’s stock after buying an additional 13,375 shares during the period. FMR LLC owned 15.15% of Presbia PLC worth $5,856,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 16.50% of the company’s stock.

Presbia PLC Company Profile

Presbia PLC is an ophthalmic device company. The Company develops and markets an optical lens implant for treating presbyopia, the age-related loss of the ability to focus on near objects. The Company’s segment is the restoration of clear vision caused by presbyopia. The Company provides the refractive lens for patient surgeries and accessories for procedures performed exclusively outside the United States.

Receive News & Ratings for Presbia PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Presbia PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.